Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 2;2(3):537-48.
doi: 10.3390/vaccines2030537.

Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses

Affiliations
Review

Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses

Graham R Leggatt. Vaccines (Basel). .

Abstract

While T cells recognise the complex of peptide and major histocompatibility complex (MHC) at the cell surface, changes in the dose and/or structure of the peptide component can have profound effects on T cell activation and function. In addition, the repertoire of T cells capable of responding to any given peptide is variable, but broader than a single clone. Consequently, peptide parameters that affect the interaction between T cells and peptide/MHC have been shown to select particular T cell clones for expansion and this impacts on clearance of disease. T cells with high functional avidity are selected on low doses of peptide, while low avidity T cells are favoured in high peptide concentrations. Altering the structure of the peptide ligand can also influence the selection and function of peptide-specific T cell clones. In this review, we will explore the evidence that the choice of peptide dose or the structure of the peptide are critical parameters in an effective vaccine designed to activate T cells.

Keywords: T cell avidity; altered peptide ligands; functional avidity; peptide dose; peptide structure; peptide vaccines; vaccination.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of the effects of variant, low and high dose peptide on effector T cell responses.

Similar articles

Cited by

References

    1. Paran N., Sutter G. Smallpox vaccines: New formulations and revised strategies for vaccination. Hum. Vaccin. 2009;5:824–831. - PMC - PubMed
    1. Lauring A.S., Jones J.O., Andino R. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 2010;28:573–579. doi: 10.1038/nbt.1635. - DOI - PMC - PubMed
    1. Bachmann M.F., Kalinke U., Althage A., Freer G., Burkhart C., Roost H., Aguet M., Hengartner H., Zinkernagel R.M. The role of antibody concentration and avidity in antiviral protection. Science. 1997;276:2024–2027. - PubMed
    1. Perrin H., Canderan G., Sekaly R.P., Trautmann L. New approaches to design HIV-1 T-cell vaccines. Curr. Opin. HIV AIDS. 2010;5:368–376. doi: 10.1097/COH.0b013e32833d2cc0. - DOI - PMC - PubMed
    1. Robinson H.L. HIV/AIDS vaccines: 2007. Clin. Pharmacol. Ther. 2007;82:686–693. doi: 10.1038/sj.clpt.6100408. - DOI - PubMed